Drug repurposing is using an existing drug for a new treatment that was not indicated before. It has received immense attention during the COVID-19 pandemic emergency. Drug repurposing has become the need of time to fasten the drug discovery process and find quicker solutions to the over-exerted healthcare scenario and drug needs. Drug repurposing involves identifying the drug, evaluating its efficiency using preclinical models, and proceeding to phase II clinical trials. Identification of the drug candidate can be made through computational and experimental approaches. This approach usually utilizes public databases for drugs. Data from primary and translational research, clinical trials, anecdotal reports regarding off-label uses, and other published human data information available are included. Using artificial intelligence algorithms and other bioinformatics tools, investigators systematically try to identify the interaction between drugs and protein targets. It can be combined with genetic data, clinical analysis, structure (molecular docking), pathways, signatures, targets, phenotypes, binding assays, and artificial intelligence to get an optimum outcome in repurposing. This article describes the strategies involved in drug repurposing and enlists a series of repurposed drugs and their indications.

Infections are the primary cause of death from burns and diabetic wounds. The clinical difficulty of treating wound infections with conventional antibiotics has progressively increased and reached a critical level, necessitating a paradigm change for enhanced chronic wound care. The most prevalent bacterium linked with these infections is Staphylococcus aureus, and the advent of community-associated methicillin-resistant Staphylococcus aureus has posed a substantial therapeutic challenge. Most existing wound dressings are ineffective and suffer from constraints such as insufficient antibacterial activity, toxicity, failure to supply enough moisture to the wound, and poor mechanical performance. Using ineffective wound dressings might prolong the healing process of a wound. To meet this requirement, nanoscale scaffolds with their desirable qualities, which include the potential to distribute bioactive agents, a large surface area, enhanced mechanical capabilities, the ability to imitate the extracellular matrix (ECM), and high porosity, have attracted considerable interest. The incorporation of nanoparticles into nanofiber scaffolds constitutes a novel approach to “nanoparticle dressing” that has acquired significant popularity for wound healing. Due to their remarkable antibacterial capabilities, silver nanoparticles are attractive materials for wound healing. This review focuses on the therapeutic applications of nanofiber wound dressings containing Ag-NPs and their potential to revolutionize wound healing.

This review article summarises and discusses the recent developments in different biomedical applications of electrospun chitosan nanofibers.

Wound healing is an unresolved therapeutic challenge for the medical community, as wound assessment and management is a complex procedure involving numerous factors that play a significant role in the healing process. Several factors, including bacterial infections, underlying conditions, malnutrition, obesity, aging, and smoking are the most frequent causes of a delayed wound-healing process. The shortcomings related to the currently used wound dressings include poor antimicrobial properties, weak mechanical features, poor biodegradability, biocompatibility, etc. Modern medicine has expanded the use of phytoconstituents based on nanotechnology to regenerate and repair soft and hard tissues. Electrospun nanofiber platforms are the most recent and promising among many types of conventional wound dressings due to their distinct characteristics. Many plant extracts and their phytoconstituents are well-known as adequate substitutes for wound healing agents because of their wide range of active ingredients, accessibility, and limited side effects. Incorporating these phytoconstituents into electrospun nanofibers combines the structural properties of the nanofibers with the antibacterial and therapeutic properties of the plants, making the nanofibers ideal for use as wound dressings. This review focuses on the antibacterial and therapeutic applications of nanofiber wound dressings containing phytoconstituents and their potential to revolutionize wound healing.

Chronic wounds impose a significant burden on individuals and healthcare systems all over the world. Through clinical and preclinical investigations, inflammation and oxidative damage have been established as the primary causes of chronic wounds. These skin sores are easily exposed to microorganisms, which in turn cause inflammation and hinder the healing process. Additionally, microorganisms may cause an infection that prevents collagen production and reepithelialization. Curcumin’s antioxidant, anti-inflammatory, and anti-infectious characteristics, among others, have been identified as useful for diabetic wound healing management. However, curcumin has a few disadvantages, such as limited bioavailability, pH-dependent instability, water insolubility, slow cell absorption, and fast intracellular metabolism. These constraints necessitates the development of a suitable transporter to improve curcumin’s stability, bioavailability, therapeutic efficacy, and solubility. In recent years, Electrospun nanofiber mats have been an excellent choice for drug delivery because of their numerous advantages and inherent properties. Electrospun nanofibers have shown considerable promise as wound dressing materials. This review highlights the potential properties and recent advancements in using curcumin-loaded nanofibers for diabetic wound healing.